De protocollen moeten in overeenstemming zijn met OESO-richtsnoer 471 (Salmonella typhimurium Reverse Mutation Test), 472 (Escherichia coli Reverse Mutation Test), 473 (in vitro Mammalian Chromosomal Aberration Test), 474 (Mammalian Erythrocyte Micronucleus Test), 475 (Mammalian Bone Marrow Chromosomal Aberration Test), 476 (in vitro Mammalian Cell Gene Mutation Test) of 482 (Unscheduled DNA Synthesis in Mammalian Cells in vitro) en met andere relevante OESO-richtsnoeren voor in-vitro- en in-vivotests.
Die Verfahren sollten einer der folgenden OECD-Leitlinien sowie sonstigen einschlägigen OECD-Leitlinien für In-vitro- und In-vivo-Tests entsprechen: 471 (Salmonella typhimurium Reverse Mutation Test), 472 (Escherichia coli Reverse Mutation Test), 473 (In vitro Mammalian Chromosome Aberration Test), 474 (Mammalian Erythrocyte Micronucleus Test), 475 (Mammalian Bone Marrow Chromosome Aberration Test), 476 (In vitro Mammalian Cell Gene Mutation Test) oder 482 (Genetic Toxicology: DNA Damage and Repair, Unscheduled DNA Synthesis in Mammalian Cells in vitro).